John Chen, PhD
Ophthalmology · Rochester, MNNPI 1437391083
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by UCB SA at 47.1% of the total. 2025 is the largest year on record at $24,444, more than ten times the $550 reported in 2019. Among ophthalmology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $1307.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$39K
- Amgen$21K
- UCB GmbH$16K
- Genentech, Inc.$2K
- AstraZeneca$2K
- Dompe Farmaceutici S.p.a.$1K
- plus $2K from 6 others
What the payments were for
- Consulting fees$41,53850%
- Speaking & faculty fees$16,53520%
- Travel & lodging$23,22428%
- Food & beverage$1,0991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 21 | $38,768 |
| Amgen(2 entities) | 24 | $20,614 |
| UCB GmbH | 4 | $15,653 |
| Genentech, Inc. | 1 | $2,400 |
| AstraZeneca | 3 | $1,764 |
| Dompe Farmaceutici S.p.a. | 1 | $1,266 |
| Merck | 3 | $1,000 |
| Biogen | 1 | $550 |
| Alcon | 2 | $246 |
| Tarsus Pharmaceuticals, Inc. | 1 | $69 |
| Boston Scientific | 1 | $33 |
| Eisai Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rystiggo$26,386
- UPLIZNA$20,181
- Enspryng$2,400
- Hydrus Microstent$144
- AcrySof IQ PanOptix$102
How this compares
$82,396 in reported general payments places this provider in the 95th percentile of 330 ophthalmology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acetazolamide ErAcetazolamide | 18 | $1,317 |
| Prednisolone Acetate | 26 | $1,086 |
| Ketorolac Tromethamine | 23 | $1,005 |
| MoxifloxacinMoxifloxacin Hcl | 28 | $657 |
| Latanoprost | 45 | $322 |
| Prednisone | 12 | $135 |
| Topiramate | 15 | $70 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Rochester
- Sophie BakriRochester$183K
- Raymond IezziRochester$44K
- Arthur SitRochester$33K
- Muhammad BhattiRochester$24K
- Brittni ScruggsRochester$21K
- Sanjay PatelRochester$20K
- Matthew StarrRochester$16K
- Lilly WagnerRochester$15K
- John WoogRochester$6K
- James GarrityRochester$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.